NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis $32.47 -0.23 (-0.70%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About XOMA Royalty Stock (NASDAQ:XOMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$32.18▼$32.7750-Day Range$24.05▼$34.2052-Week Range$18.35▼$35.22Volume3,492 shsAverage Volume44,467 shsMarket Capitalization$392.56 millionP/E RatioN/ADividend YieldN/APrice Target$69.50Consensus RatingModerate Buy Company Overview XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Read More XOMA Royalty Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreXOMA MarketRank™: XOMA Royalty scored higher than 83% of companies evaluated by MarketBeat, and ranked 192nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingXOMA Royalty has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXOMA Royalty has only been the subject of 1 research reports in the past 90 days.Read more about XOMA Royalty's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for XOMA Royalty are expected to grow in the coming year, from ($1.41) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA Royalty is -21.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA Royalty is -21.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA Royalty has a P/B Ratio of 5.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA Royalty's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.54% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in XOMA Royalty has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA Royalty does not currently pay a dividend.Dividend GrowthXOMA Royalty does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-0.22 Percentage of Shares Shorted2.54% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in XOMA Royalty has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.92 News SentimentXOMA Royalty has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for XOMA Royalty this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for XOMA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XOMA Royalty insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.10% of the stock of XOMA Royalty is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA Royalty's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMA Stock News HeadlinesAnalysts Set Expectations for XOMA Royalty FY2026 EarningsAugust 24, 2025 | americanbankingnews.comXoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy RatingAugust 22, 2025 | tipranks.comWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.August 29 at 2:00 AM | Reagan Gold Group (Ad)Mural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural OncologyAugust 20, 2025 | quiverquant.comQMural Oncology to be acquired by XOMA unit for up to $2.24/share in cashAugust 20, 2025 | seekingalpha.comMural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 MillionAugust 20, 2025 | quiverquant.comQMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20, 2025 | globenewswire.comLeerink Partnrs Expects Reduced Earnings for XOMA RoyaltyAugust 19, 2025 | americanbankingnews.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA Royalty's stock was trading at $26.28 at the beginning of the year. Since then, XOMA stock has increased by 24.4% and is now trading at $32.70. How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) announced its earnings results on Wednesday, August, 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.60. The biotechnology company earned $13.13 million during the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive trailing twelve-month return on equity of 2.63%. Who are XOMA Royalty's major shareholders? Top institutional investors of XOMA Royalty include BVF Inc. IL (21.64%), Opaleye Management Inc. (2.13%), Geode Capital Management LLC (1.70%) and Stonepine Capital Management LLC (1.27%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Joseph M Limber and Bradley Sitko. View institutional ownership trends. How do I buy shares of XOMA Royalty? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2025Today8/29/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$69.50 High Price Target$104.00 Low Price Target$35.00 Potential Upside/Downside+114.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.82 million Net Margins-27.57% Pretax Margin-34.07% Return on Equity2.63% Return on Assets0.97% Debt Debt-to-Equity Ratio1.41 Current Ratio4.88 Quick Ratio4.88 Sales & Book Value Annual Sales$28.49 million Price / Sales13.78 Cash FlowN/A Price / Cash FlowN/A Book Value$5.99 per share Price / Book5.42Miscellaneous Outstanding Shares12,090,000Free Float10,988,000Market Cap$392.56 million OptionableOptionable Beta1.00 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:XOMA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.